TCTAP A-079 Clinical Efficacy and Safety of Bioresorbable Vascular Scaffold in an Unselected Patient Population: A Single Centre Real World Experience

TCTAP A-079 Clinical Efficacy and Safety of Bioresorbable Vascular Scaffold in an Unselected Patient Population: A Single Centre Real World Experience

The primary endpoint was in-hospital major adverse cardiac events (MACE) ie a composite of cardiovascular death, target vessel related myocardial infarction (MI) and target lesion revascularization (TLR).

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2014-04, Vol.63 (12), p.S22-S23
Hauptverfasser: Ching, Min Er, Ho, Hee Hwa, Ooi, Yau Wei, Beng, Ko, Tan, Julian, Loh, Kwok Kong, Yin, Nwe Tun, Jafary, Fahim Haider, Lueng Ong, Paul Jau
Format: Artikel
Sprache:eng
Schlagworte:
Acute coronary syndromes
Cardiology
Cardiovascular
Cardiovascular disease
Heart attacks
Internal Medicine
Patients
Thrombosis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The primary endpoint was in-hospital major adverse cardiac events (MACE) ie a composite of cardiovascular death, target vessel related myocardial infarction (MI) and target lesion revascularization (TLR).
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2014.02.096